Pfizer’s RSV vaccine shows benefit in immunosuppressed adults
Pfizer said its respiratory syncytial virus (RSV) vaccine, Abrysvo, generated a strong immune response in a late-stage study of four groups of adults aged 18 years and older with a compromised immune system.
ПОПУЛЯРНЫЕ ПОСТЫ
Poland prepares for peaking floods
Сентябрь 20, 2024
Italy evacuates thousands as Boris hits the north
Сентябрь 20, 2024
China and the US race to tame nuclear fusion for clean energy
Сентябрь 20, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ